A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive disease
Abstract Introduction The cytoskeletal protein ezrin is upregulated in many cancer types and is strongly associated with poor patient outcome. While the clinical and prognostic value of ezrin has been previously evaluated in breast cancer, most studies to date have been conducted in smaller cohorts...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5802 |
| _version_ | 1797817659736195072 |
|---|---|
| author | Sarah J. Storr Victoria Hoskin Radhika Aiyappa‐Maudsley Abdi Ghaffari Sonal Varma Andrew Green Emad Rakha Ian O. Ellis Peter A. Greer Stewart G. Martin |
| author_facet | Sarah J. Storr Victoria Hoskin Radhika Aiyappa‐Maudsley Abdi Ghaffari Sonal Varma Andrew Green Emad Rakha Ian O. Ellis Peter A. Greer Stewart G. Martin |
| author_sort | Sarah J. Storr |
| collection | DOAJ |
| description | Abstract Introduction The cytoskeletal protein ezrin is upregulated in many cancer types and is strongly associated with poor patient outcome. While the clinical and prognostic value of ezrin has been previously evaluated in breast cancer, most studies to date have been conducted in smaller cohorts (less than 500 cases) or have focused on specific disease characteristics. The current study is the largest of its kind to evaluate ezrin both at the protein and mRNA levels in early‐stage breast cancer patients using the Nottingham (n = 1094) and METABRIC (n = 1980) cohorts, respectively. Results High expression of ezrin was significantly associated with larger tumour size (p = 0.027), higher tumour grade (p < 0.001), worse Nottingham Prognostic Index prognostic group (p = 0.011) and HER2‐positive status (p = 0.001). High ezrin expression was significantly associated with adverse survival of breast cancer patients (p < 0.001) and remained associated with survival in multivariate Cox‐regression analysis (p = 0.018, hazard ratio (HR) = 1.343, 95% confidence interval (CI) = 1.051–1.716) when potentially confounding factors were included. High ezrin expression was significantly associated with adverse survival of patients whose tumours were categorised as receptor (oestrogen receptor (ER), progesterone receptor (PgR) or HER2) positive (p < 0.001) in comparison to those categorised as triple‐negative breast cancer (p = 0.889). High expression of ezrin mRNA (VIL2) in the METABRIC cohort was also significantly associated with adverse survival of breast cancer patients (p < 0.001). Conclusion Retrospective analyses show that ezrin is an independent prognostic marker, with higher expression associated with shortened survival in receptor‐positive (ER, PgR or HER2) patients. Ezrin expression is associated with more aggressive disease and may have clinical utility as a biomarker of patient prognosis in early‐stage breast cancer. |
| first_indexed | 2024-03-13T08:56:45Z |
| format | Article |
| id | doaj.art-c970806911ed436fa210b513806aa37c |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-13T08:56:45Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-c970806911ed436fa210b513806aa37c2023-05-28T20:33:59ZengWileyCancer Medicine2045-76342023-05-01129109081091610.1002/cam4.5802A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive diseaseSarah J. Storr0Victoria Hoskin1Radhika Aiyappa‐Maudsley2Abdi Ghaffari3Sonal Varma4Andrew Green5Emad Rakha6Ian O. Ellis7Peter A. Greer8Stewart G. Martin9Nottingham Breast Cancer Research Centre, Biodiscovery Institute University of Nottingham, School of Medicine Nottingham UKDivision of Cancer Biology and Genetics, Queen's Cancer Research Institute Queen's University Kingston Ontario CanadaNottingham Breast Cancer Research Centre, Biodiscovery Institute University of Nottingham, School of Medicine Nottingham UKDivision of Cancer Biology and Genetics, Queen's Cancer Research Institute Queen's University Kingston Ontario CanadaDepartment of Pathology and Molecular Medicine Queen's University Kingston Ontario CanadaNottingham Breast Cancer Research Centre, Biodiscovery Institute University of Nottingham, School of Medicine Nottingham UKNottingham Breast Cancer Research Centre, Biodiscovery Institute University of Nottingham, School of Medicine Nottingham UKNottingham Breast Cancer Research Centre, Biodiscovery Institute University of Nottingham, School of Medicine Nottingham UKDivision of Cancer Biology and Genetics, Queen's Cancer Research Institute Queen's University Kingston Ontario CanadaNottingham Breast Cancer Research Centre, Biodiscovery Institute University of Nottingham, School of Medicine Nottingham UKAbstract Introduction The cytoskeletal protein ezrin is upregulated in many cancer types and is strongly associated with poor patient outcome. While the clinical and prognostic value of ezrin has been previously evaluated in breast cancer, most studies to date have been conducted in smaller cohorts (less than 500 cases) or have focused on specific disease characteristics. The current study is the largest of its kind to evaluate ezrin both at the protein and mRNA levels in early‐stage breast cancer patients using the Nottingham (n = 1094) and METABRIC (n = 1980) cohorts, respectively. Results High expression of ezrin was significantly associated with larger tumour size (p = 0.027), higher tumour grade (p < 0.001), worse Nottingham Prognostic Index prognostic group (p = 0.011) and HER2‐positive status (p = 0.001). High ezrin expression was significantly associated with adverse survival of breast cancer patients (p < 0.001) and remained associated with survival in multivariate Cox‐regression analysis (p = 0.018, hazard ratio (HR) = 1.343, 95% confidence interval (CI) = 1.051–1.716) when potentially confounding factors were included. High ezrin expression was significantly associated with adverse survival of patients whose tumours were categorised as receptor (oestrogen receptor (ER), progesterone receptor (PgR) or HER2) positive (p < 0.001) in comparison to those categorised as triple‐negative breast cancer (p = 0.889). High expression of ezrin mRNA (VIL2) in the METABRIC cohort was also significantly associated with adverse survival of breast cancer patients (p < 0.001). Conclusion Retrospective analyses show that ezrin is an independent prognostic marker, with higher expression associated with shortened survival in receptor‐positive (ER, PgR or HER2) patients. Ezrin expression is associated with more aggressive disease and may have clinical utility as a biomarker of patient prognosis in early‐stage breast cancer.https://doi.org/10.1002/cam4.5802breast cancerEZRezrinVIL2 |
| spellingShingle | Sarah J. Storr Victoria Hoskin Radhika Aiyappa‐Maudsley Abdi Ghaffari Sonal Varma Andrew Green Emad Rakha Ian O. Ellis Peter A. Greer Stewart G. Martin A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive disease Cancer Medicine breast cancer EZR ezrin VIL2 |
| title | A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive disease |
| title_full | A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive disease |
| title_fullStr | A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive disease |
| title_full_unstemmed | A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive disease |
| title_short | A retrospective analysis of ezrin protein and mRNA expression in breast cancer: Ezrin expression is associated with patient survival and survival of patients with receptor‐positive disease |
| title_sort | retrospective analysis of ezrin protein and mrna expression in breast cancer ezrin expression is associated with patient survival and survival of patients with receptor positive disease |
| topic | breast cancer EZR ezrin VIL2 |
| url | https://doi.org/10.1002/cam4.5802 |
| work_keys_str_mv | AT sarahjstorr aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT victoriahoskin aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT radhikaaiyappamaudsley aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT abdighaffari aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT sonalvarma aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT andrewgreen aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT emadrakha aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT ianoellis aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT peteragreer aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT stewartgmartin aretrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT sarahjstorr retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT victoriahoskin retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT radhikaaiyappamaudsley retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT abdighaffari retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT sonalvarma retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT andrewgreen retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT emadrakha retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT ianoellis retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT peteragreer retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease AT stewartgmartin retrospectiveanalysisofezrinproteinandmrnaexpressioninbreastcancerezrinexpressionisassociatedwithpatientsurvivalandsurvivalofpatientswithreceptorpositivedisease |